Engineered immune cells take aim at debilitating muscle weakness
NCT ID NCT07714798
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This early-phase trial tests a single infusion of universal STAR-T cells—engineered immune cells—in adults aged 18 to 65 with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The study aims to assess safety, tolerability, and signs of effectiveness, with participants followed for up to two years. It is conducted at a single hospital in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a cell therapy called universal STAR-T cells
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat generalized myasthenia gravis.
- What could go wrong
- This is an early, small phase 1 trial focused on safety, so it may not show clear benefit. Cell therapies can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
- New drug trial aims to ease muscle weakness in rare disease
- New shot could ease daily struggles for myasthenia gravis patients
- New study lets myasthenia gravis patients rate their own symptoms on a new drug
- New CAR-T therapy aims to calm overactive immune system in muscle weakness disease